Information Provided By: 
Fly News Breaks for June 30, 2016
AGN
Jun 30, 2016 | 08:21 EDT
Leerink analyst Jason Gerberry says that, according to two aesthetic specialists he met with, the market for toxins and fillers for wrinkles should continue to grow at a healthy pace and Allergan is expected to remain a preferred supplier. The analyst is "increasingly confident" that the company's $2B facial injectable business will be a key growth driver in the next 3-5 yrs. Gerberry reiterates an Outperform rating and $272 price target on the shares.
News For AGN From the Last 2 Days
There are no results for your query AGN
